Skip to main content
SpringerLink
Log in

ASO Author Reflections: Innovative HIPEC Organoid Models and Mucolytics: Targeted Therapeutic Use of Bromelain for Appendiceal Cancer

  • ASO Author Reflections
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Chicago Consensus Working Group. The Chicago Consensus on peritoneal surface malignancies: management of appendiceal neoplasms. Ann Surg Oncol. 2020;27:1753–60. https://doi.org/10.1245/s10434-020-08316-w.

    Article  Google Scholar 

  2. Valenzuela CD, et al. Repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for cancers with peritoneal metastasis: a 30-year institutional experience. Ann Surg Oncol. 2022;29:3436–45. https://doi.org/10.1245/s10434-022-11441-3.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Votanopoulos KI, et al. Appendiceal cancer patient-specific tumor organoid model for predicting chemotherapy efficacy prior to initiation of treatment: a feasibility study. Ann Surg Oncol. 2019;26:139–47. https://doi.org/10.1245/s10434-018-7008-2.

    Article  PubMed  Google Scholar 

  4. Forsythe SD, et al. Personalized identification of optimal HIPEC perfusion protocol in patient-derived tumor organoid platform. Ann Surg Oncol. 2020;27:4950–60. https://doi.org/10.1245/s10434-020-08790-2.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Wajih N, Erali R, Forsythe S, et al. Enhancing the efficacy of HIPEC through Bromelain: a preclinical investigation in appendiceal cancer. Ann Surg Oncol. 2024. https://doi.org/10.1245/s10434-024-15355-0.

    Article  PubMed  Google Scholar 

Download references

Funding

This research stems from the Wake Forest Organoids Research Center and was supported by Wake Forest Institute for Regenerative Medicine, the Tumor Tissue and Pathology Shared Resource, Mucpharm Pty Ltd, and the Appendix Cancer Pseudomyxoma Peritonei Foundation (ACPMP).

Author information

Authors and Affiliations

  1. Wake Forest Organoid Research Center (WFORCE), Winston-Salem, NC, USA

    Richard A. Erali MD, MPH, Nadeem Wajih PhD & Konstantinos I. Votanopoulos MD, PhD

  2. Wake Forest Institute of Regenerative Medicine (WFIRM), Winston-Salem, NC, USA

    Richard A. Erali MD, MPH, Nadeem Wajih PhD & Konstantinos I. Votanopoulos MD, PhD

  3. Department of Surgery, St. George Hospital, University of New South Wales, Sydney, Australia

    Richard A. Erali MD, MPH, David L. Morris MD, PhD & Konstantinos I. Votanopoulos MD, PhD

  4. Division of Surgical Oncology, Department of Surgery, Atrium Health Wake Forest Baptist Health, Wake Forest University, Medical Center Boulevard, Winston Salem, NC, USA

    Richard A. Erali MD, MPH & Konstantinos I. Votanopoulos MD, PhD

Authors
  1. Richard A. Erali MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nadeem Wajih PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David L. Morris MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Konstantinos I. Votanopoulos MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Konstantinos I. Votanopoulos MD, PhD.

Ethics declarations

Disclosures

The authors declare no conflicts of interest except Dr. David Morris, who is CEO and co-founder of Mucpharm Pty Ltd and provided bromelain materials and additional financial support for this work. Dr. Konstantinos Votanopoulos declares that Organoid released patents.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article refers to: Wajih N, Erali R, Forsythe S, et al. Enhancing the efficacy of HIPEC through Bromelain: A preclinical investigation in appendiceal cancer. Ann Surg Oncol (2024). https://doi.org/10.1245/s10434-024-15355-0.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Erali, R.A., Wajih, N., Morris, D.L. et al. ASO Author Reflections: Innovative HIPEC Organoid Models and Mucolytics: Targeted Therapeutic Use of Bromelain for Appendiceal Cancer. Ann Surg Oncol (2024). https://doi.org/10.1245/s10434-024-15428-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1245/s10434-024-15428-0

Search

Navigation